Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AllerPops
- Development stage
- Unknown
- Lead developer
- AllerPops
- Modality
- Microbiome Therapeutics
- Administration
- Oral
01
Overview
AllerPops is a prebiotic-based consumer health product developed by AllerPops Corp to address seasonal allergies by supporting the oral microbiome. The product contains a proprietary blend of nutrients, including amino acids and sugars, designed to promote the growth of beneficial oral bacteria. According to the developer, these bacteria help regulate the immune system's response to allergens, potentially reducing symptoms like sneezing and congestion. It is marketed as a natural alternative to antihistamines and is delivered in the form of a lollipop to ensure prolonged contact with the oral mucosa.
- Brand names
- AllerPops
- Other names
- AllerPops Prebiotic Lollipops
Beyond the preview
Go deeper on AllerPops.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AllerPops.